Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) from a hold rating to a buy rating in a research note published on Monday morning. FOLD has been the topic of several other research reports. BTIG Research boosted their price target on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company […]

Related Keywords

China ,Johnf Crowley ,Michael Raab ,China Universal Asset Management Co ,Amicus Therapeutics Inc ,Securities Exchange Commission ,Amicus Therapeutics ,Goldman Sachs Group ,Associates Corp ,First Horizon Advisors Inc ,Get Rating ,Moderate Buy ,Director Michael Raab ,Exchange Commission ,Chairman John ,Universal Asset Management ,Horizon Advisors ,Amicus Therapeutics Daily ,Nasdaq Fold ,Fold ,Medical ,03152w10 ,Upgrade ,Stocknews Com ,